About Us

Cloudbreak Pharma is a clinical stage ophthalmic drug company, founded September 2015 in Irvine, CA, USA. Our team has diverse skill sets and extensive ocular drug R&D experience.


Our eyes are a tool for much more than vision. We use them to connect and communicate with the people and world around us. Cloudbreak Pharma is on a mission to ensure no one is held back by poor eye health. We aim to help people prosper by treating a variety of eye conditions that compromise vision and quality of life.

We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that are amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.


Jinsong Ni, PhD Cloudbreak Therapeutics Founder and CEO

Jinsong Ni, Ph.D

Founder, Chief Executive Officer


Rebecca Chan, CPA, MBA, LLB

Director, Chief Financial Officer

Abu Abraham

Abu Abraham, MD

Chief Medical Officer

Van Dinh MBA Cloudbreak Therapeutics Co-Founder and COO

Van Dinh, MBA

Chief Operating Officer

我的專案 (1)

Rong Yang, Ph.D

Chief Scientific Officer


Greg Brooks, B.Sc

Chief Commercial Officer

WenKui Fang

W. Ken Fang, Ph.D

Chief Innovation Officer

Elizabeth Capan

Elizabeth Capan, J.D.

Chief Patent Officer

Scientific Advisory Board